BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22147940)

  • 1. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.
    Chimge NO; Baniwal SK; Luo J; Coetzee S; Khalid O; Berman BP; Tripathy D; Ellis MJ; Frenkel B
    Clin Cancer Res; 2012 Feb; 18(3):901-11. PubMed ID: 22147940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2.
    Chimge NO; Baniwal SK; Little GH; Chen YB; Kahn M; Tripathy D; Borok Z; Frenkel B
    Breast Cancer Res; 2011; 13(6):R127. PubMed ID: 22151997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
    Bedard PL; Singhal SK; Ignatiadis M; Bradbury I; Haibe-Kains B; Desmedt C; Loi S; Evans DB; Michiels S; Dixon JM; Miller WR; Piccart MJ; Sotiriou C
    Endocr Relat Cancer; 2011 Dec; 18(6):721-30. PubMed ID: 21984694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
    Miller WR; Larionov A
    Breast Cancer Res; 2010; 12(4):R52. PubMed ID: 20646288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
    Masri S; Liu Z; Phung S; Wang E; Yuan YC; Chen S
    Breast Cancer Res Treat; 2010 Nov; 124(1):89-99. PubMed ID: 20054641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
    Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
    Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ER
    Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
    Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
    [No Abstract]   [Full Text] [Related]  

  • 8. Stopping treatment can reverse acquired resistance to letrozole.
    Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
    Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    Brodie A; Jelovac D; Sabnis G; Long B; Macedo L; Goloubeva O
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):41-8. PubMed ID: 15967659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.
    Baniwal SK; Khalid O; Gabet Y; Shah RR; Purcell DJ; Mav D; Kohn-Gabet AE; Shi Y; Coetzee GA; Frenkel B
    Mol Cancer; 2010 Sep; 9():258. PubMed ID: 20863401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
    Abrhale T; Brodie A; Sabnis G; Macedo L; Tian C; Yue B; Serrero G
    BMC Cancer; 2011 Jun; 11():231. PubMed ID: 21658239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole.
    Rawat A; Gopal G; Selvaluxmy G; Rajkumar T
    Cell Oncol (Dordr); 2013 Dec; 36(6):459-67. PubMed ID: 24072565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    Ellis MJ; Tao Y; Young O; White S; Proia AD; Murray J; Renshaw L; Faratian D; Thomas J; Dowsett M; Krause A; Evans DB; Miller WR; Dixon JM
    J Clin Oncol; 2006 Jul; 24(19):3019-25. PubMed ID: 16754938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
    Tilghman SL; Townley I; Zhong Q; Carriere PP; Zou J; Llopis SD; Preyan LC; Williams CC; Skripnikova E; Bratton MR; Zhang Q; Wang G
    Mol Cell Proteomics; 2013 Sep; 12(9):2440-55. PubMed ID: 23704778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
    Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
    J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
    Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
    J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letrozole-induced functional changes in carcinoma-associated fibroblasts and their influence on breast cancer cell biology.
    Li K; Kang H; Wang Y; Hai T; Rong G; Sun H
    Med Oncol; 2016 Jul; 33(7):64. PubMed ID: 27235140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.